TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03832309

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speaking to them as a regualar person
Description: During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speaking to them as a regualar person
Description: During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
Study: NCT01660191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastin 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastin 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg
Study: NCT00818129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7295
Description: ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple ascending dose (tbd based on single dose results), oral solution
Study: NCT04310956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Y-Knot all-suture anchor
Description: Y-knot all-suture anchor will be implanted to participants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biocomposite suture anchor
Description: Biocomposite suture anchor will be implanted to participants
Study: NCT02214368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early application of NIV
Description: Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy
Description: Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional application of NIV
Description: Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.
Study: NCT01684163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13 5 mg/kg
Description: Intravenous administration of 5 mg/kg into arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13 10 mg/kg
Description: Intravenous administration of 10 mg/kg into arm.
Study: NCT03943147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Specified dose on specified days
Study: NCT04932044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Receives routine care and provide general discharge care and nursing guidance.
Study: NCT01826526

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TauroSept®
Description: 5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TauroSept®
Description: 5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months.
Study: NCT02920606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment
Study: NCT00753688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZOPANIB
Description: 800 mg once daily orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo 800 mg once daily orally
Study: NCT01929265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28
Study: NCT01684163

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of normal saline into arm.
Study: NCT03003273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stoppage of antibiotics
Description: antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: amoxycillin/clavulanic acid
Description: In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
Study: NCT02961166

Intervention type: DRUG
Intervention: IgM enriched Immunoglobulins
Description: Treatment for 3 days
Study: NCT04412148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intralesional injection of saline
Study: NCT03254602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound Treatment
Study: NCT02619877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to diabetic foot ulcer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy conducted for patients with diabetic foot ulcer
Study: NCT04527055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG
Description: Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline Pill
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study: NCT02825446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty tibial arteries
Description: Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon
Description: Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time.
Study: NCT01673659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study: NCT01370304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS and active Venlafaxine
Description: rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS and sham Venlafaxine
Description: rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS and active Venlafaxine
Description: rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks
Study: NCT02745496

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TRUS Biopsy
Description: Standard of Care Treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TRUS/FUSION Biopsy
Description: Interventional Treatment
Study: NCT00521677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sage oral care
Description: Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional oral care
Description: Cleaning of oral cavity with menthol solution, TID
Study: NCT01890096

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR 2 Fraction
Description: High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR 1 Fraction
Description: High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
Study: NCT05060692

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloot testing
Description: NFL measruments in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloot testing
Description: NFL measruments in serum
Study: NCT01952743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation with Renal Denervation
Description: Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation alone
Description: Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
Study: NCT03856359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 milligrams (MG)
Description: Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
Study: NCT04149483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
Study: NCT00310375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine: USAN Retigabine (International Nonproprietary Name)
Description: Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
Study: NCT02982655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized BP lowering

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized BP lowering
Study: NCT01718522

Intervention type: DEVICE
Intervention: sensor augmented pump (SAP)
Study: NCT00573391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade, Thalidomide, and Dexamethasone
Description: Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade, Melphalan, and Dexamethasone
Description: Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles
Study: NCT00871663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT00774124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
Study: NCT02669199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
Study: NCT04613999

Intervention type: DRUG
Group type: OTHER
Intervention: Ralinepag
Description: Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
Study: NCT02729805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10ml bolus injection of saline followed by intravenous infusion of saline during the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.5mg/kg
Description: 0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.75mg/kg
Description: 0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
Study: NCT02289274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: NVP-1203(eperisone SR + aceclofenac)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone SR tab. + and Airtal tab.
Description: Eperisone SR and aceclofenac
Study: NCT00373100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc acetate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03040765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 60 MG/ML Prefilled Syringe
Description: Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
Study: NCT03046043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation
Description: pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation
Description: pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Voltage & CFAE guided ablation
Description: In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
Study: NCT00431821

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Home-based exercise prescriptions with weekly motivational telephone calls.

Intervention type: OTHER
Group type: OTHER
Intervention: Stroke education
Description: Stroke education program with matched attention phone calls
Study: NCT02072382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 850mg twice a day for eight weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04055987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual biofeedback, auditory feedback and models
Description: The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual biofeedback, auditory feedback and models
Description: The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.